Novartis committed $200 million upfront to Arrowhead Pharmaceuticals to license and co-develop ARO-SNCA, an RNA interference therapy targeting alpha-synuclein protein implicated in Parkinson’s disease and related synucleinopathies. The deal includes potential milestones up to $2.2 billion. Arrowhead’s Targeted RNAi Molecule (TRiM) platform facilitates efficient delivery of siRNA therapeutics to the central nervous system via subcutaneous administration. The partnership aligns Novartis with cutting-edge RNAi technology to pursue novel neurodegenerative disease treatments.